CN101031565B - 取代的2h-1,3-苯并噁嗪-4(3h)-酮 - Google Patents

取代的2h-1,3-苯并噁嗪-4(3h)-酮 Download PDF

Info

Publication number
CN101031565B
CN101031565B CN2005800328848A CN200580032884A CN101031565B CN 101031565 B CN101031565 B CN 101031565B CN 2005800328848 A CN2005800328848 A CN 2005800328848A CN 200580032884 A CN200580032884 A CN 200580032884A CN 101031565 B CN101031565 B CN 101031565B
Authority
CN
China
Prior art keywords
alkyl
compound
halogen
och
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800328848A
Other languages
English (en)
Chinese (zh)
Other versions
CN101031565A (zh
Inventor
罗伯特·M·斯卡伯勒
明纳卡什·S·文卡特拉曼
张晓明
安贾莉·潘迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of CN101031565A publication Critical patent/CN101031565A/zh
Application granted granted Critical
Publication of CN101031565B publication Critical patent/CN101031565B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2005800328848A 2004-09-29 2005-09-26 取代的2h-1,3-苯并噁嗪-4(3h)-酮 Expired - Fee Related CN101031565B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61456404P 2004-09-29 2004-09-29
US60/614,564 2004-09-29
PCT/US2005/034246 WO2006039212A2 (en) 2004-09-29 2005-09-26 Substituted 2h-1,3-benzoxazin-4(3h)-ones

Publications (2)

Publication Number Publication Date
CN101031565A CN101031565A (zh) 2007-09-05
CN101031565B true CN101031565B (zh) 2010-09-29

Family

ID=36142983

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800328848A Expired - Fee Related CN101031565B (zh) 2004-09-29 2005-09-26 取代的2h-1,3-苯并噁嗪-4(3h)-酮

Country Status (13)

Country Link
US (1) US7205296B2 (enExample)
EP (1) EP1812429A4 (enExample)
JP (1) JP2008514703A (enExample)
KR (1) KR20070064356A (enExample)
CN (1) CN101031565B (enExample)
AU (1) AU2005292314B2 (enExample)
BR (1) BRPI0516181A (enExample)
CA (1) CA2581638A1 (enExample)
IL (1) IL182180A0 (enExample)
MX (1) MX2007003836A (enExample)
NZ (1) NZ554211A (enExample)
WO (1) WO2006039212A2 (enExample)
ZA (1) ZA200702688B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834023B2 (en) 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
US7740693B2 (en) * 2007-10-01 2010-06-22 Honeywell International Inc. Organic fluorescent sulfonyl ureido benzoxazinone pigments
CA2853439A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CA2855019A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
WO2013177224A1 (en) * 2012-05-22 2013-11-28 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
HK1213181A1 (zh) 2012-09-27 2016-06-30 Portola Pharmaceuticals, Inc. 雙環氧雜內酰胺激酶抑制劑
BR112015022488A2 (pt) 2013-03-14 2017-07-18 Genentech Inc triazolopiridinas substituídas e métodos de uso das mesmas
EP2970156B1 (en) 2013-03-15 2018-07-25 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
JP6383418B2 (ja) 2013-11-27 2018-08-29 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
KR102523430B1 (ko) 2014-08-04 2023-04-19 누에볼루션 에이/에스 염증성, 대사성, 종양성 및 자가면역성 질환의 치료에 유용한 피리미딘의 임의적 융합 헤테로시클릴-치환 유도체
RS60906B1 (sr) 2014-10-06 2020-11-30 Vertex Pharma Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu
PT3578547T (pt) 2015-02-16 2021-06-22 The Provost Fellows Found Scholars And Other Members Of Board Of College Of Holy And Undivided Trini Sulfonilureias e compostos relacionados e uso dos mesmos
CR20170591A (es) 2015-05-22 2018-05-07 Genentech Inc Benzamidas sustituidas y métodos para utilizarlas
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
PE20181003A1 (es) 2015-09-28 2018-06-26 Genentech Inc Compuestos terapeuticos y sus metodos de uso
WO2017091592A1 (en) 2015-11-25 2017-06-01 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
HUE056716T2 (hu) 2016-09-30 2022-03-28 Vertex Pharma Cisztás firbrózis transzmembrán konduktancia regulátor modulátora, gyógyszerészeti készítmények, kezelési eljárások, és eljárások a modulátor elõállítására
MA46546A (fr) 2016-10-17 2021-05-05 Genentech Inc Composés thérapeutiques et leurs procédés d'utilisation
EP3812379A1 (en) 2016-12-09 2021-04-28 Vertex Pharmaceuticals Incorporated Crystalline form of a n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide for treating cystic fibrosis
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
PT3661925T (pt) 2017-07-07 2022-01-31 Inflazome Ltd Novos compostos de sulfonamida-carboxamida
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
WO2019034692A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
UY37847A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
EP3694861A4 (en) 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
EP3707137A1 (en) 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
MX2020004423A (es) 2017-11-09 2020-08-06 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida.
JP7245834B2 (ja) 2017-12-08 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019165290A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
CN113939296A (zh) 2019-04-09 2022-01-14 诺维逊生物股份有限公司 杂环化合物及其用途
EP3952879A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
US20220168313A1 (en) * 2019-04-09 2022-06-02 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
JP7450980B2 (ja) * 2019-12-10 2024-03-18 シャンハイ ジムン バイオファーマ，インコーポレーテッド 神経保護効果を有する化合物およびその調製方法と用途
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1099032A (zh) * 1993-03-08 1995-02-22 合成实验室公司 苯并噁嗪衍生物，其制备方法及其药用
US6166246A (en) * 1996-10-18 2000-12-26 Ihara Chemical Industry Co., Ltd. 4-fluorosalicyclic acid derivative and process for production thereof
WO2004052871A1 (ja) * 2002-12-06 2004-06-24 Toray Industries, Inc. ベンゾモルホリン誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
JP2002509152A (ja) 1998-01-15 2002-03-26 シーオーアール セラピューティクス インコーポレイテッド 血小板ａｄｐ受容体阻害剤
CA2332608C (en) 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
US6509348B1 (en) 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
ATE309999T1 (de) 2000-02-04 2005-12-15 Portola Pharm Inc Blutplättchen-adp-rezeptor-inhibitoren
ATE357457T1 (de) 2000-11-01 2007-04-15 Astellas Pharma Inc Verfahren zum screenen eines plättchenhemmers
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
CN1863789B (zh) * 2003-10-03 2010-06-09 博尔托拉制药公司 取代的异喹啉酮
DE602004024093D1 (de) * 2003-10-03 2009-12-24 Portola Pharm Inc 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1099032A (zh) * 1993-03-08 1995-02-22 合成实验室公司 苯并噁嗪衍生物，其制备方法及其药用
US6166246A (en) * 1996-10-18 2000-12-26 Ihara Chemical Industry Co., Ltd. 4-fluorosalicyclic acid derivative and process for production thereof
WO2004052871A1 (ja) * 2002-12-06 2004-06-24 Toray Industries, Inc. ベンゾモルホリン誘導体

Also Published As

Publication number Publication date
NZ554211A (en) 2010-10-29
MX2007003836A (es) 2007-08-20
BRPI0516181A (pt) 2008-08-26
ZA200702688B (en) 2008-06-25
WO2006039212A3 (en) 2007-01-25
AU2005292314A1 (en) 2006-04-13
US7205296B2 (en) 2007-04-17
JP2008514703A (ja) 2008-05-08
US20060069093A1 (en) 2006-03-30
CN101031565A (zh) 2007-09-05
AU2005292314B2 (en) 2011-11-03
WO2006039212A2 (en) 2006-04-13
IL182180A0 (en) 2007-07-24
HK1111414A1 (en) 2008-08-08
CA2581638A1 (en) 2006-04-13
EP1812429A2 (en) 2007-08-01
KR20070064356A (ko) 2007-06-20
EP1812429A4 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
CN101031565B (zh) 取代的2h-1,3-苯并噁嗪-4(3h)-酮
TWI304062B (en) N-(pyridin-2-yl)-sulfonamide derivatives
JP5112423B2 (ja) ピリドピリミジノン誘導体
US8552015B2 (en) Quinazolinone derivatives and their use as CB agonists
IL174446A (en) 2,4-dioxo-3-quinazolinylaryl sulfonylurea derivatives and pharmaceutical compositions containing the same
JPH06507625A (ja) アンギオテンシンｉｉアンタゴニストとしての酸官能基を有する置換ピリミジノン
TW200402294A (en) Chemical compounds
CN1323076C (zh) 4,4－二氟－1,2,3,4－四氢－5h－1－苯并氮杂䓬衍生物或其盐
TW200902532A (en) Aza-pyridopyrimidinone derivatives
CN103974955B (zh) 嘧啶并-哒嗪酮化合物及其用途
NZ522226A (en) Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
CN101616667A (zh) 可用作激酶抑制剂的杂环酰胺化合物
Ruminski et al. Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2 S, 5 R)-5-(hydroxymethyl)-1, 4-dioxan-2-yl) methyl)-2 H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis
CN101316829A (zh) 具有crth2受体活性的噁二唑衍生物
KR20090057314A (ko) 혈소판 ａｄｐ 수용체 억제제로서의 질소를 포함하는 치환된 헤테로사이클
AU2219599A (en) Platelet adp receptor inhibitors
CA2269814A1 (en) 2-methoxyphenylpiperazine derivatives
CN101490061A (zh) 噻二唑化合物和其使用方法
Yang et al. Novel dabigatran derivatives with a fluorine atom at the C-2 position of the terminal benzene ring: Design, synthesis and anticoagulant activity evaluation
Modica et al. Design, synthesis and binding properties of novel and selective 5-HT3 and 5-HT4 receptor ligands
US20060142268A1 (en) 1,4,5,6-tetrahydroimidazo[4,5-d]benzazepine derivative or salt thereof
CN102219759B (zh) 芳基甲酰胺类化合物及其制备方法、药物组合物和用途
JP2003277263A (ja) 医薬組成物
HK1111414B (en) Substituted 2h-1,3-benzoxazin-4(3h)-ones
JPH03232885A (ja) キナゾリン誘導体およびその塩

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1111414

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1111414

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100929

Termination date: 20120926